Latest Ratios: P/E Ratio -0.0x · EV/EBITDA N/A · ROE -227.9%. (2013–2023 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $10733 | $221M | $45M | $204M | $500M | $278M | $182M | $247M | $154M | — | — |
| Enterprise Value | $-77440267 | $143M | $-58547235 | $177M | $392M | $262M | $132M | $215M | $96M | — | — |
| P/E Ratio → | -0.00 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 0.00 | 22.21 | 3.05 | 8.68 | 33.11 | 140.23 | 88.73 | 224.53 | 487.03 | — | — |
| P/B Ratio | 0.00 | 13.24 | 0.36 | 2.39 | 5.52 | 3.51 | 2.31 | 3.78 | 1.92 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 14.41 | -3.93 | 7.53 | 25.96 | 132.40 | 64.41 | 195.33 | 302.91 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 77.3% | 77.3% | 80.1% | 100.0% | 100.0% | 100.0% | 100.0% | -38.7% | 100.0% | -89.9% | — |
| Operating Margin | -1298.2% | -1298.2% | -913.1% | -423.3% | -545.3% | -3922.4% | -3136.4% | -4966.9% | -15130.3% | -9406.9% | — |
| Net Profit Margin | -1656.3% | -1656.3% | -636.1% | -368.5% | -556.8% | -3806.2% | -3038.0% | -4905.5% | -15060.9% | -9406.3% | — |
| Metric | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -227.9% | -227.9% | -88.9% | -98.5% | -99.0% | -95.6% | -86.6% | -74.0% | -83.3% | -63.2% | -41.8% |
| ROA | -79.8% | -79.8% | -44.3% | -43.7% | -46.3% | -58.8% | -67.2% | -63.6% | -70.8% | -56.7% | -40.4% |
| ROIC | — | — | -248.7% | -364.7% | -265.8% | -126.2% | -155.8% | -148.0% | -347.3% | — | -100762.5% |
| ROCE | -74.7% | -74.7% | -74.4% | -59.2% | -52.9% | -72.8% | -83.9% | -74.0% | -81.7% | -62.2% | -41.8% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 3.73 | 3.73 | 0.50 | 0.76 | 0.73 | 0.33 | 0.00 | 0.00 | 0.00 | 0.01 | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -4.65 | -0.81 | -0.32 | -1.19 | -0.20 | -0.63 | -0.49 | -0.72 | -1.04 | -1.00 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -31.10 | -31.10 | -21.90 | -21.15 | -45.90 | — | -62279.00 | — | — | — | — |
Net cash position: cash ($140M) exceeds total debt ($62M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.95 | 3.95 | 6.87 | 4.33 | 6.24 | 4.87 | 5.21 | 5.89 | 8.94 | 4.58 | 48.36 |
| Quick Ratio | 3.95 | 3.95 | 6.87 | 4.33 | 6.24 | 4.86 | 5.21 | 5.89 | 8.94 | 4.58 | 48.36 |
| Cash Ratio | 3.80 | 3.80 | 6.57 | 4.14 | 6.08 | 3.89 | 5.10 | 5.80 | 8.74 | 4.51 | 48.24 |
| Asset Turnover | — | 0.06 | 0.06 | 0.13 | 0.07 | 0.01 | 0.02 | 0.01 | 0.00 | 0.01 | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | 41.55 | 46.29 | 56.37 | 3712.25 | — | — | 998.28 | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.2% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.2% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $28M | $13M | $6M | $5M | $4M | $3M | $3M | $1M | $247557 | $247557 |
Includes 30+ ratios · 11 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying SYRS stock.
Syros Pharmaceuticals, Inc.'s current P/E ratio is -0.0x. This places it at the 50th percentile of its historical range.
Syros Pharmaceuticals, Inc.'s return on equity (ROE) is -227.9%. The historical average is -108.4%.
Based on historical data, Syros Pharmaceuticals, Inc. is trading at a P/E of -0.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Syros Pharmaceuticals, Inc. has 77.3% gross margin and -1298.2% operating margin.
Key Metrics
Top Statement Risk
Clinical Trial Funding Gap
Metrics are mathematically derived from official filings.
Negative Margins Reflect R&D Intensity
As reported in financial statements, Syros Pharmaceuticals exhibits a deeply negative operating margin of -1298.19%, underscoring the company's status as a pre-commercial entity where R&D expenditures vastly outweigh the intermittent, milestone-driven revenue streams that have historically characterized the firm's top-line performance.
The reported gross margin of 77.33% is an accounting artifact of collaboration-based revenue and should not be interpreted as a proxy for future manufacturing profitability. Investors should monitor the transition from milestone-based income to commercial product sales, as the current margin profile is unsustainable without a successful regulatory outcome for Tamibarotene.
Liquidity Constraints Amidst Cash Burn
According to recent SEC filings, the company's current ratio has fluctuated significantly, reaching 2.25 in 2024Q3, which suggests that while short-term assets remain available, the rapid depletion of cash reserves necessitates a cautious outlook regarding the firm's ability to fund operations through pivotal clinical data readouts.
The reliance on non-recurring milestone payments creates a volatile liquidity profile that is highly sensitive to the timing of clinical trial progress. Given the lack of recurring revenue, the current liquidity position appears vulnerable to any delays in the SELECT-MDS program, which would likely force further dilutive financing.
Working Capital Volatility and Leverage
Based on reported figures, the company's days payable outstanding (DPO) has reached 2422 days in 2024Q3, indicating an extreme reliance on extended payment terms with suppliers to preserve cash, a trend that warrants further investigation into the sustainability of these vendor relationships during periods of financial stress.
The lack of meaningful asset turnover, which has hovered near zero, confirms that the company is not currently generating value from its capital base through operational activities. This inefficiency is a structural byproduct of the clinical-stage business model, where capital is deployed into intangible R&D assets rather than revenue-generating inventory or equipment.
Misapplication of Traditional Valuation Multiples
As indicated by the provided data, the use of P/E or EV/EBITDA ratios is fundamentally inappropriate for Syros Pharmaceuticals, as these metrics obscure the company's lack of recurring earnings and the high-risk, binary nature of its clinical-stage pipeline which is not captured by standard accounting valuation models.
Investors should instead focus on the cash runway and the probability-weighted net present value of the Tamibarotene program. Relying on traditional multiples in this context may lead to a significant mispricing of the firm's long-term viability, as the current financial statements do not reflect the potential value of the proprietary gene control platform.